First children vaccinated in Moderna's Phase 2/3 pediatric trial

First children vaccinated in Moderna's Phase 2/3 pediatric trial   The first children have been vaccinated in Moderna's Phase 2/3 pediatric Covid-19 vaccine trial, the company announced Tuesday in a statement.   The clinical trial, called the KidCOVE study, will enroll approximately 6,750 children in the US and Canada between the ages of 6 months and 11 years old.   The trial is broken into two parts. In part one, different doses of the vaccine are being tested on the children. Children between the ages of 6 months and 1 year old will receive two doses of the vaccine, spaced about 28 days apart, at either a 25 or a 50 or a 100 microgram level. Children between the ages of 2 and 11 will receive two doses of the vaccine, spaced about 28 days apart, at either a 50 or a 100 microgram level.   The findings of part one will be used to determine which dose will be used in part two. For part two, the trial will expand to include children who are given a saline placebo shot, which does nothing. The children will be followed for 12 months after their second injection.   Moderna is not the only Covid-19 vaccine currently being tested in children, as the Pfizer/BioNTech Covid-19 vaccine is being studied in children as well. Johnson & Johnson has announced plans to study the vaccine in adolescents, ages 12 to 18.